Related Experiment Video
Updated: Mar 20, 2026

Comparative Analysis of Automatic Fecal Analyzer versus Direct Wet Smear Microscopy for Detecting Parasitic Infections in Stool Samples
Published on: April 25, 2025
Fecal diagnostics in combination with serology: best test to establish STEC-HUS
Kioa L Wijnsma1, Sheila A M van Bommel2, Thea van der Velden3
1Department of Pediatric Nephrology, Radboudumc Amalia Children's Hospital, Radboud University Medical Center, P.O. Box 1901, 6500 HB, Nijmegen, Netherlands. Kioa.Wijnsma@radboudumc.nl.
Insights
Diagnosing Shiga toxin-producing E. coli (STEC) hemolytic-uremic syndrome (HUS) is improved by a new antibody test. This serological assay detects STEC O157 antibodies, aiding diagnosis when stool tests are negative.
Area of Science:
- Pediatric Nephrology
- Infectious Diseases
- Clinical Microbiology
Background:
- Hemolytic-uremic syndrome (HUS) in children is often caused by Shiga toxin-producing E. coli (STEC), primarily serotype O157.
- Distinguishing STEC-HUS from atypical HUS is crucial due to differing treatments and prognoses.
- Standard fecal diagnostic tests for STEC may miss infections due to the short detection window of the pathogen and its toxins.
Purpose of the Study:
- To evaluate the diagnostic added value of a serological assay detecting immunoglobulin M (IgM) antibodies against STEC O157 lipopolysaccharide (LPS).
- To determine if this assay improves the detection rate of STEC-HUS, especially when standard fecal tests are inconclusive or performed late in the disease course.
Main Methods:
- Retrospective analysis of clinical and microbiological data from 65 pediatric patients with STEC-HUS treated between 1990 and 2014.
- Detection of IgM antibodies against STEC O157 LPS using an enzyme-linked immunosorbent assay (ELISA).
- Comparison of diagnostic yield between fecal testing and the addition of the serological assay.
Main Results:
- Fecal diagnostic tests confirmed STEC infection in 54% of patients.
- The serological assay identified an additional 16 patients with STEC O157 infection, representing a 23% increase in diagnostic yield (p < 0.0001).
- The added diagnostic value of the serological assay was most significant for samples collected more than 7 days after symptom onset.
Conclusions:
- The anti-O157 LPS antibody assay significantly enhances the diagnosis of STEC-HUS when used alongside standard fecal tests.
- This serological test provides crucial diagnostic information, particularly in later disease stages.
- Incorporation of this assay into routine clinical practice is recommended for improved STEC-HUS diagnosis.
Background:
In the majority of pediatric patients, the hemolytic-uremic syndrome (HUS) is caused by an infection with Shiga toxin-producing Escherichia coli (STEC), mostly serotype O157. It is important to discriminate between HUS caused by STEC and complement-mediated HUS (atypical HUS) due to differences in treatment and outcome. As STEC and its toxins can only be detected in the patient's stool for a short period of time after disease onset, the infectious agent may go undetected using only fecal diagnostic tests. Serum antibodies to lipopolysaccharide (LPS) of STEC persist for several weeks and may therefore be of added value in the diagnosis of STEC.
Methods:
All patients with clinical STEC-HUS who were treated at Radboud University Medical Center between 1990 and 2014 were included in this retrospective single-center study. Clinical and diagnostic microbiological data were collected. Immunoglobulin M (IgM) antibodies against LPS of STEC serotype O157 were detected by a serological assay (ELISA).
Results:
Data from 65 patients weres available for analysis. Fecal diagnostic testing found evidence of an STEC infection in 34/63 patients (54 %). Serological evidence of STEC O157 was obtained in an additional 16 patients. This is an added value of 23 % (p < 0.0001) when the serological antibody assay is used in addition to standard fecal diagnostic tests to confirm the diagnosis STEC-HUS. This added value becomes especially apparent when the tests are performed more than 7 days after the initial manifestation of the gastrointestinal symptoms.
Conclusions:
The serological anti-O157 LPS assay clearly makes a positive contribution when used in combination with standard fecal diagnostic tests to diagnose STEC-HUS and should be incorporated in clinical practice.
Related Concept Videos
Bacterial Gastroenteritis
Serum Laboratory Studies, Stool Test, Breath Test
Automated Microbial Diagnostics

